News By Tag
News By Location
The Institute of Addiction Medicine appoints Joseph R. Volpicelli, MD, Ph.D. as CEO
The Institute of Addiction Medicine (IAM) is pleased to announce the appointment of Joseph R. Volpicelli, M.D., PhD as CEO and President. In this role he will define the mission and strategic goals of the Institute’s philanthropy.
By: Rochelle Redding
During the past twenty five years, Dr. Volpicelli has pioneered the integration of medications with psychotherapy support to treat addictions. His research on the use of Naltrexone led to the first new medication to be approved by the FDA for alcohol treatment in nearly 50 years.
Throughout this time he was an Associate Professor of Psychiatry at the University of Pennsylvania and Senior Scientist at the Pennsylvania VA Center for Research on Addictive Disorders. Dr. Volpicelli is also the author of “Recovery Options: The Complete Guide” and “Combining Medication and Psychosocial Treatments for Addictions: The Brenda Approach”.
IAM is dedicated to finding novel evidence based treatments through clinical research and the dissemination of this research through scientific publications and conferences. Dr. Volpicelli will facilitate the establishment of clinical treatment programs starting with the Volpicelli Center. These programs are being developed to address the growing need for addiction treatment and clinical training programs to teach health care providers how to deliver evidence based treatments.
IAM plans to sponsor expert panels to review clinical research and make recommendations for best practices. They will also offer Training and Research Fellowships to train the next generation of future scientists and clinicians.
# # #
IAM was formed to address an important need in Addiction Treatment, namely to bring evidence based treatments into clinical practice. IAM seeks to enhance the understanding and treatment of substance abuse addictions.